Clinical Trial Update: Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating frontline T-cell engager versus autologous stem cell transplant with MRD-guided sequential intensification for newly diagnosed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM) | Phase 2 | Status: RECRUITING